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HMGA1 proteins are architectural transcription factors that are overexpressed by pancreatic adenocarcinomas. Roles of HMGA1 in
mediating the malignant phenotype of this cancer are poorly understood. We tested the hypothesis that overexpression of HMGA1
promotes resistance to anoikis (apoptosis induced by anchorage deprivation) in pancreatic cancer cells. HMGA1 cDNA was stably
transfected into MiaPaCa2 human pancreatic adenocarcinoma cells (which have low baseline expression levels of HMGA1). Cells
were grown in suspension on PolyHEMA-coated plates and their susceptibility to anoikis was assayed using flow cytometry.
Overexpression of HMGA1 was associated with marked reductions in susceptibility to anoikis in concert with increases in Akt
phosphorylation (Ser473) and in Akt kinase activity and with reductions in caspase 3 activation. Inhibition of phosphoinositidyl-3 (PI3-
K)/Akt pathway with either the small molecule inhibitor LY294002 or dominant-negative Akt resulted in reversal of anoikis resistance
induced by HMGA1 overexpression. Further, RNA interference-mediated HMGA1 silencing in MiaPaCa2 and BxPC3 (a human
pancreatic adenocarcinoma cell line with high baseline levels of HMGA1 expression) cells resulted in significant increases in
susceptibility to anoikis. Our findings suggest HMGA1 promotes anoikis resistance through a PI3-K/Akt-dependent mechanism. Given
the putative associations between anoikis resistance and metastatic potential, HMGA1 represents a potential therapeutic target in
pancreatic adenocarcinoma.
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Pancreatic adenocarcinoma is among the deadliest of all human
cancers, with 5-year survival rates averaging less than 5% (Jemal
et al, 2006). The propensity for pancreatic adenocarcinoma cells to
metastasise early in the course of disease progression makes this
cancer particularly refractory to standard therapies. Characterising
the underlying mechanisms mediating metastatic dissemination in
pancreatic adenocarcinoma may reveal novel targets for inhibiting
this process, which is so aggressive in this cancer.
Anoikis, derived from a Greek word meaning ‘homelessness’,
was used in describing the observation that depriving cells from
attachment to matrix triggers apoptosis in these cells (Frisch and
Francis, 1994). Increasingly, metastasis is conceptualised to be a
multistep process facilitated by the evolution of anoikis-resistant
subsets of cancer cells that are capable of surviving in the blood
stream during dissemination after they detach from the primary
tumour and its stroma. Indeed, numerous studies suggest a close
correlation between signalling events mediating cellular anoikis
resistance in vitro and those mediating metastatic potential in vivo
(Yawata et al, 1998; Zhu et al, 2001; Douma et al, 2004;
Berezovskaya et al, 2005).
The human HMGA1 gene, located on chromosomal locus 6p21,
encodes two HMGA1 splice variants (HMGA1a and HMGA1b)
(Friedmann et al, 1993). These HMGA1 proteins are architectural
transcription factors that regulate gene expression in vivo by
forming stereo-specific, multiprotein complexes termed ‘enhan-
ceosomes’ on the promoter regions of genes (Reeves and Nissen,
1990; Thanos and Maniatis, 1995). HMGA1 proteins are over-
expressed in a range of human cancers, notably including
pancreatic adenocarcinoma (Abe et al, 2000; Balcerczak et al,
2003; Chiappetta et al, 2004; Czyz et al, 2004; Donato et al, 2004;
Chang et al, 2005; Sarhadi et al, 2006; Xu et al, 2004). Moreover,
high tumoural expression of HMGA1 has been reported to be
predictive of poor prognosis among patients with cancer (Tamimi
et al, 1996; Balcerczak et al, 2003; Chiappetta et al, 2004).
Although these correlative data suggest a potential role for
HMGA1 in cancer pathogenesis, the underlying biology of HMGA1
in the context of cancer progression is poorly understood. The
purpose of this study was to test the hypothesis that HMGA1
promotes anoikis resistance in pancreatic adenocarcinoma. Our
observations indicate that HMGA1 promotes anoikis resistance
through the phosphoinositidyl-3 kinase (PI3-K)/Akt pathway.
MATERIALS AND METHODS
Cells and cell culture
MiaPaCa2 and BxPC3 human pancreatic ductal adenocarcinoma
cells were obtained from American Type Culture Collection
(ATCC; Manassas, VA, USA). Cells were maintained in DMEM
containing 10% fetal bovine serum (FBS) (Gibco Life Technologies
Inc., Gaithersburg, MD, USA) and incubated in a humidified
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s(371C, 5% CO2) incubator, grown in 75-cm
2 culture flasks, and
passaged on reaching 80% confluence.
Reagents and dominant-negative Akt adenovirus
The PI3-K-inhibitor LY294002 was purchased from Calbiochem
(San Diego, CA, USA). Anti-HMGA1, anti-lamin B and anti-Akt
antibodies were obtained from Santa Cruz Biotechnology (Santa
Cruz, CA, USA). Anti-phospho Akt (ser473) antibody was obtained
from Cell Signaling Technology (Danvers, MA, USA). Adenovirus
expressing dominant-negative murine Akt1 and control virus
(Ad-CMV-null) (both titred at 1 10
10PFUml
 1) were purchased
from Vector Biolabs (Philadelphia, PA, USA). Adenoviral infection
was performed at multiplicity of infection of 10 in the presence of
6mgml
 1 polybrene for 12h. Experiments were performed on cells
48h following infection.
Expression vector and transfection
The HMGA1-coding sequence was PCR amplified from IMAGE
clone 5399570 (GenBank accession no. BC063434) using gene-
specific primers modified to include the appropriate restriction
sites at their 50 end. The primers used were: forward, 50-
TTTTGATATCATGAGTGAGTCGAGCTCGAAG-30 and backward,
50-TTTTGAATTCTCACTGCTCCTCCTCCGAGGA-30. Purified PCR
products were digested with EcoRV and EcoRI, before ligation into
a EcoRV/EcoRI-digested pIRES-puro3 vector (Clontech, Palo Alto,
CA, USA). The expression plasmid was named pIRES-HMGA1.
MiaPaCa2 cells were transfected with pIRES-HMGA1 or empty
pIRES-puro3, which acted as a control, using Lipofectamine 2000
(Invitrogen, Carlsbad, CA, USA) in accordance with the manu-
facturer’s protocol. Stable clones were selected by exposure to
incrementally increasing concentrations of puromycin (Invivogen,
San Diego, CA, USA), isolated using cloning cylinders and
maintained in medium containing 3mgml
 1 puromycin
(Invivogen). Clones pIRES-HMGA1.1 and pIRES-HMGA1.2, which
expressed the highest levels of HMGA1, were used for further
studies.
Lentivirus-mediated HMGA1 RNAi
Lentiviral hairpin RNA interference (RNAi) plasmids (pLKO.1-
HMGA1, TRCN0000018949), constructed as described previously
(Stewart et al, 2003), were obtained from the RNAi Consortium
(Mission TRC Hs. 1.0, Sigma Aldrich, St Louis, MO, USA).
The sequence of short hairpin RNA (shRNA) targeting the
human HMGA1 gene (GenBank accession no. NM_002131) was
50-AACTCCAGGAAGGAAACCAA-30, corresponding to the coding
region positions 446–466. The controls were lentiviral particles
produced with empty pLKO.1 and pLKO.1, which has a scramble
nontargeting shRNA sequence obtained from Addgene (Cambridge,
MA, USA), deposited by Dr David Sabatini (Sarbassov et al, 2005).
Each of these vectors had been sequence-verified. Vectors were
expanded in chemically competent Escherichia coli (TOP10 cells,
Invitrogen) and purified using Genelute maxiprep kit (Sigma
Aldrich). To generate lentiviral particles, human embryonic kidney
293 cells (ATCC) were cotransfected with the lentiviral vector and
compatible packaging plasmid mixture (Virapower lentiviral
packaging system, Invitrogen) using Lipofectamine 2000 (Invitro-
gen), in accordance to manufacturer’s instruction. Pancreatic
adenocarcinoma cells were exposed to lentivirus-containing
supernatant for 16h in the presence of 6mgml
 1 polybrene
(Sigma, St Louis, MI, USA). Pooled stable transfectants were
established using puromycin selection. Stable transfectant cells
were maintained in medium containing 3mgml
 1 of puromycin
(Invivogen).
Anoikis induction and flow cytometry
Anoikis was assayed by plating cells on polyHEMA-coated plates. A
solution of 120mgml
 1 polyHEMA (Sigma) in 100% ethanol was
made and diluted 1:10 in 95% ethanol; 0.95mlmm
 2 of this solution
was overlaid onto 35-mm wells and left to dry in a heated dryer
system for 12h. Before use, wells were washed twice with PBS and
once with DMEM. In all, 1 10
6 cells of each line, suspended in 2ml
DMEM with 10% FBS were incubated in the polyHEMA-coated wells
for 12–18h in a humidified (371C, 5% CO2) incubator. Cells were
harvested and resuspended in 0.3ml of PBS containing 2% FBS and
0.1mM EDTA. Apoptosis staining was performed using 1mlml
 1 YO-
PRO-1 and propidium iodide (Vybrant Apoptosis Assay Kit #4;
Molecular Probes, Eugene, OR, USA). Cells were incubated for
30min on ice and then analysed by flow cytometry (FACScan;
Becton Dickinson, Franklin Lakes, NJ, USA), measuring fluorescence
emission at 530 and 575nm. Cells stained with the green fluorescent
dye YO-PRO-1 were counted as apoptotic; necrotic cells were stained
with propidium iodide. The number of apoptotic cells was divided
by the total number of cells (minimum of 10
4 cells), resulting in the
apoptotic fraction. Data were analysed using CellQuest software
(Becton Dickinson). All assays were performed in triplicates.
Western blotting
Cells were harvested and rinsed twice with PBS. Total cell extracts
were prepared with lysis buffer (20mM Tris, pH 7.5, 0.1% Triton X,
0.5% deoxycholate, 1mM PMSF, 10mgml
 1, aprotinin, 10mgml
 1
leupeptin) and cleared by centrifugation at 15000g,4 1C. Nuclear
extracts were prepared using NE-PER nuclear and cytoplasmic
extraction reagents based on the manufacturer’s instruction
(Pierce, Rockford, IL, USA). Total protein concentration was
measured using the BCA assay kit (Sigma) with bovine serum
albumin as a standard, according to the manufacturer’s instruc-
tions. Total cell lysates containing 50mg total protein or nuclear
protein containing 10mg total protein were subjected to 10%
SDS/PAGE and the resolved proteins transferred electrophoretically
to PVDF membranes (Invitrogen). Equal protein loading was
confirmed by Coomassie (BioRad, Hercules, CA, USA) staining of
the gel. After blocking with PBS containing 3% bovine serum
albumin for 1h at room temperature, membranes were incubated
with 3–5mgml
 1 antibody in PBS containing 0.1% Tween-20
overnight at 41C. Chemoluminescensce detection (Amersham
Biosciences, Piscataway, NJ, USA) was performed in accordance
with the manufacturer’s instructions. The densitometric signal was
quantified using ImagePro Plus software version 4.0 (Media
Cybernetics, Silver Spring, MD, USA) and normalised to that of
loading control as appropriate. Blots were performed in triplicate
in at least three independent experiments. Mean densitometric
values (7standard Deviation (s.d.)) are shown.
Fluorometric real-time Akt kinase assay
Assay was performed using the Omnia Lysate Akt kinase assay
(Biosource-Invitrogen, Carlsbad, CA, USA), according to the
manufacturer’s instructions. Briefly, total cell lysate equivalent
to 5mgml
 1 was loaded into each well. Following addition of
fluorescent Akt substrates and kinase buffer, fluorescent signal was
acquired real-time (excitation, 360nm; emission, 485nm) for
60min using SpectraMax M5 microplate reader (Molecular
Devices, Sunnyvale, CA, USA). The Akt kinase activity was
calculated from the slope of activity curve. Experiments were
performed in triplicates on at least three occasions.
Fluorometric caspase profiling
Whole-cell lysates were assayed for caspases 3 activity using the
BD ApoAlert Caspase Assay Plate (BD Biosciences Clontech, Palo
HMGA1 and anoikis resistance
S-S Liau et al
994




















sAlto, CA, USA) according to the manufacturer’s instructions.
Plates were read (excitation, 360nm; emission, 480nm) using
SpectraMax M5 microplate reader in fluorescence mode (Mole-
cular Devices). All measurements were performed in triplicate,
each with three determinations for each condition.
Proliferation assay
Cell proliferation was quantified using an MTS (3-(4,5 dime-
thylthiazol-2-yl)-5-(3-carboxymethoxyphenyl-2-(4-sulfophenyl)-
2H-tetrazolium) assay (CellTiter 96 Aqueous One Solution Assay,
Promega, Madison, WI, USA), in accordance to the manufacturer’s
instructions and confirmed by cell counting. Logarithmically
growing cells were seeded into 96-well plates at 5 10
3 cells per
well and allowed to adhere overnight in medium containing 10%
FBS. Cell proliferation was determined after 48h. Plates were read
with the use of the SpectraMax M5 microplate spectrophotometer
(Molecular Devices) at a wavelength of 490nm. Ten samples
were used for each experimental condition and experiments were
performed in triplicate. At identical time points, cell counting was
performed. Cells were trypsinised to form a single-cell suspension.
Viable cells, determined by trypan blue exclusion, were counted
with the use of a Neubauer hemocytometer (Hausser Scientific,
Horsham, PA, USA).
Statistical analysis
Differences between groups were analysed using Student’s t-test,
multifactorial ANOVA of initial measurements and Mann–
Whitney U-test for nonparametric data, as appropriate, using
Statistica 5.5 software (StatSoft Inc., Tulsa, OK, USA). In cases in
which averages were normalised to controls, the s.d. of each
nominator and denominator were taken into account in calculating
the final s.d.. Po0.05 was considered statistically significant.
RESULTS
HMGA1 overexpression promotes anoikis resistance in
MiaPaCa2 pancreatic adenocarcinoma cells
Stable overexpression of HMGA1 was achieved in MiaPaCa2 cells,
which have low inherent expression levels of HMGA1. Two stable
HMGA1-overexpressing clones were selected and named pIRES-
HMGA1.1 and pIRES-HMGA1.2. HMGA1 overexpression was
confirmed on Western blot analysis (Figure 1). Levels of HMGA1
overexpression in pIRES-HMGA1.1 and pIRES-HMGA1.2 were
four- and 3.5-fold higher than in control cells, respectively. There
was no difference in the levels of HMGA1 expression between the
empty pIRES-puro3 transfectants and parental MiaPaCa2 cells.
Following 18h of anchorage-deprivation (on polyHEMA plates),
pIRES-HMGA1.1 and pIRES-HMGA1.2 clones showed significantly
increased anoikis resistance (mean anoikis fractions of 11 and
13%, respectively) when compared to controls (mean anoikis
fractions for parental MiaPaCa2 and empty pIRES-puro3 transfec-
tants were 26 and 27%, respectively, Figure 2A and 2B).
HMGA1 overexpression results in protection from caspase-
mediated apoptosis
Given that disruption of cell–matrix interactions can trigger
anoikis via caspase-dependent apoptosis, we examined the effects
of HMGA1 overexpression on caspase 3 activity (a central
mediator of apoptosis) in the context of anchorage deprivation.
During induction of anoikis on polyHEMA plates, HMGA1-
overexpressing clones demonstrated markedly reduced levels of
caspase 3 activity compared to parental MiaPaCa2 or pIRES-puro3
controls (Figure 2C).
Overexpression of HMGA1 increases levels of Akt
phosphorylation and Akt kinase activity
PI3-K/Akt-signalling pathway is of critical importance in mediat-
ing anoikis resistance and enhancing anchorage-independent
cell cycle progression (Moore et al, 1998; Nguyen et al, 2002).
Given these observations, we sought to determine if HMGA1
overexpression would modulate Akt phosphorylation at Ser473,
a marker of Akt activation. HMGA1 overexpression resulted in
elevated Akt (Ser473) phosphorylation (Figure 3A). Consistent
with this finding, HMGA1 overexpression was found to be
associated with increases in Akt kinase activity (Figure 3B).
Inhibition of Pl3-K/Akt signalling reverses HMGA1
overexpression-induced anoikis resistance
Having demonstrated that HMGA1 overexpression induces con-
stitutive activation of PI3-K/Akt pathway, we next examined the
effects of inhibiting this pathway in cells overexpressing HMGA1.
First, we used a specific small molecule inhibitor of PI3-K,
LY294002, to assess the effects of inhibiting PI3-K on anoikis
resistance of these cells. Addition of 25mM of LY294002
significantly increased anoikis fractions in pIRES-HMGA1.1 and
pIRES-HMGA1.2 clones (Figure 3C). Treatment of parental
MiaPaCa2 and empty pIRES-puro3 controls with LY294002 also
inhibited anoikis resistance, although to lesser extent than for
pIRES-HMGA1.1 and pIRES-HMGA1.2 clones. Second, infection
of pIRES-HMGA1.1 and pIRES-HMGA1.2 clones with adenovirus
expressing a dominant-negative Akt construct also significantly









































































































































Figure 1 Two stable transfectant clones derived from MiaPaCa2 cells
were confirmed to overexpress HMGA1 (pIRES-HMGA1.1 and 1.2) on
Western blot analysis of nuclear extracts. Lamin B was used as a loading
control. Controls were parental MiaPaCa2 cells or cells stably transfected
with empty pIRES-puro3 vector. *Blots shown are representative of three
independent experiments. Densitometry values, normalised to Lamin B
signals, are mean7s.d.. Po0.05 vs empty pIRES-puro3 vector and parental
MiaPaCa2 cells.
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s(Figure 3D). Parental MiaPaCa2 and empty pIRES-puro3 controls
also exhibited increased anoikis fractions with infection of
adenovirus expressing dominant-negative Akt construct, but to a
lesser extent than the HMGA1-overexpressing clones. Taken
together, these results suggest that HMGA1 overexpression-
induced anoikis resistance is dependent on PI3-K/Akt signalling.
Targeted RNAi of HMGA1 in MiaPaCa2 and BxPC3
pancreatic adenocarcinoma cells increases susceptibility
to anoikis
Given the effects of HMGA1 overexpression on anoikis resistance
in MiaPaCa2 cells, we asked if silencing of HMGA1 in the same cell
line will have the reverse effects. In addition, we also selected
BxPC3 pancreatic adenocarcinoma cell line for RNAi experiments
as these cells have high levels of HMGA1 expression at baseline. In
these lentivirus-mediated RNAi experiments, we developed pooled
stable transfectants. Stable transfectants derived from infection
with lentivirus developed from empty PLKO.1 and scramble
shRNA transfer plasmids served as controls. We achieved at least
90% silencing of HMGA1 expression in both MiaPaCa2 and BxPC3
cells (Figure 4A). Of note, neither HMGA1 overexpression nor
silencing had any impact on lamin B expression (used to normalise
for protein loading, Figures 1 and 4A). HMGA1 silencing was
associated with significant increases in anoikis fractions in both
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Figure 2 (A, B) Forced HMGA1 overexpression protects MiaPaCa2 cells, which have low inherent expression of HMGA1, from anoikis. Representative
flow cytometric images are shown with anoikis fractions highlighted in the inserted square (Figure 2A). Clones pIRES-HMGA1.1 and pIRES-HMGA1.2
exhibited 2- to 2.5-fold reductions in anoikis fraction compared to parental MiaPaCa2 cells and pIRES-puro3 control stable transfectants (Figure 2B).
*Po0.05 vs parental MiaPaCa2 cells or empty pIRES-puro3 transfectants. (C) HMGA1 overexpression protects MiaPaCa2 cells from caspase-mediated
anoikis. pIRES-HMGA1.1 and pIRES-HMGA1.2 clones showed significant reductions in caspase 3 activity, compared to parental MiaPaCa2 cells and empty
pIRES-puro3 transfectants, following induction of anoikis on polyHEMA plates for 18h. *Po0.05 vs parental MiaPaCa2 cells or empty pIRES-puro3
transfectants.
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sModulation of HMGA1 expression did not have an impact on
growth characteristics of pancreatic adenocarcinoma cells
Neither overexpression (Figure 5A) nor targeted suppression of
HMGA1 expression (Figure 5B) had any impact on proliferation
rates of pancreatic adenocarcinoma cells studied.
DISCUSSION
Pancreatic adenocarcinoma is associated with dismal prognosis,
in large part resulting from metastatic disease, even in patients
initially deemed to be surgically resectable. We have focused our












































































































































































































































































DMSO controls Controls adenovirus
Dominant negative Akt adenovirus 25 µM LY294002
A B
C D
Figure 3 (A) Overexpression of HMGA1 led to increased activation of Akt, as evident from increased levels of phospho-Akt (Ser473), a marker of Akt
activation. Both pIRES-HMGA1.1 and pIRES-HMGA1.2 clones exhibited a higher degree of Akt phosphorylation compared to control cells. There were no
differences in the level of expression of total Akt with overexpression of HMGA1. *Po0.05 vs parental MiaPaCa2 cells or empty pIRES-puro3 transfectants. Blot
shown is representative of three independent experiments. (B) Correspondingly, overexpression of HMGA1 results in increased Akt kinase activities as
determined by fluorometric real-time Akt kinase assays. Slope of Akt kinase activity curves indicates the levels of Akt kinase activity. Representative results of Akt
kinase activity assay from three independent experiments are shown. pIRES-HMGA1.1 and pIRES-HMGA1.2 clones showed steeper activity curve slopes and
hence Akt kinase activities, when compared to empty pIRES-puro3 controls. *Po0.05 vs empty pIRES-puro3 vector transfectants. (C) Anoikis resistance induced
by HMGA1 overexpression in pIRES-HMGA1.1 and pIRES-HMGA1.2 clones was reversed by preincubating cells in 25mM LY294002, a specific inhibitor of PI3-K.
Inhibiting PI3-K resulted in increases in anoikis fractions in pIRES-HMGA1.1 and pIRES-HMGA1.2 clones to levels similar to parental MiaPaCa2 and empty pIRES-
puro3 controls. Controls were cells treated with the DMSO vehicle. *Po0.05 vs DMSO controls. (D) Similarly, infection of pIRES-HMGA1.1 and pIRES-HMGA1.2
clones with adenovirus carrying dominant-negative Akt1 resulted in reversal of anoikis resistance with increases in anoikis fractions in both HMGA1-overexpressing
clones. Controls were cells infected with adenovirus expressing an empty CMV promoter (Ad-CMV-null). *Po0.05 vs control adenovirus (Ad-CMV-null).
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Figure 4 (A) Using lentivirus-mediated RNAi of HMGA1, we achieved up to 90% silencing of HMGA1 expression in both MiaPaCa2 and BxPC3 cell
lines. A representative Western blot performed on nuclear extracts showing the degree of HMGA1 silencing is shown. Controls were stable transfectants
developed following infection with lentivirus expressing empty PLKO.1 or scramble RNAi sequence. (B) Silencing of HMGA1 promoted anoikis in both cell
lines following culture in polyHEMA plates for 18 (for MiaPaCa2) and 12h (for BxPC3). Representative images of flow cytometric analyses of anoikis
fractions with apoptotic populations highlighted in triangles drawn are shown. Targeted suppression of HMGA1 resulted in significant increases in anoikis
fractions in both MiaPaCa2 and BxPC3 cells compared to empty PLKO.1 and scramble RNAi-stable transfectants. *Po0.05 vs empty PLKO.1 or scramble
RNAi transfectants.
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spancreatic adenocarcinoma, with the goal of rationally identifying
molecular targets that can be exploited to inhibit this process. In
our work, we have used anoikis resistance as an in vitro correlate
of metastatic potential. In this study, we have shown that HMGA1
overexpression confers anoikis resistance to pancreatic adeno-
carcinoma cells by activating the prosurvival PI3-K/Akt signalling
pathway. This is the first report describing a regulatory role of
HMGA1 on Akt signalling in a cancer model.
Numerous reports have described HMGA1 overexpression to be
prevalent in a wide range of human malignancies. Increasingly,
tumoural HMGA1 expression status is reported to have
prognostic value among patients with cancer (Sarhadi et al,
2006). Recently, data suggesting mechanisms by which HMGA1
may mediate cancer progression have begun to emerge. For
example, HMGA1 proteins have been demonstrated to promote
tumour progression and epithelial–mesenchymal transition in
human breast epithelial cells (Reeves et al, 2001). In immortalised
rat embryonic fibroblast Rat1a cells, HMGA1 was found to be a
c-Jun-target gene and its suppression by antisense methodology
was found to reduce the ability of c-Jun-overexpressing cells to
grow under anchorage-independent conditions (Hommura et al,
2004).
Although previous reports have implicated HMGA1 as having
the capacity to promote tumourigenesis and anchorage-indepen-
dent growth in normal epithelial cells (Reeves et al, 2001), no
studies reported to date have examined specifically the role of
HMGA1 in mediating anoikis resistance in the context of cancer
cells. Our findings suggest that HMGA1 overexpression represents
a molecular determinant of anoikis resistance in pancreatic
adenocarcinoma cells. The biological significance of this finding
relates to emerging understanding that anoikis resistance is a
phenotypic hallmark of metastatic cancer cells (Chuma et al, 2004;
Douma et al, 2004). Although the underlying mechanisms
rendering anoikis resistance in cancer cells are incompletely
understood, our findings provide evidence for a novel role for
HMGA1 in mediating this process. Further, our findings provide a
potential mechanism by which HMGA1 overexpression induces
anoikis resistance: activation of the antiapoptotic PI3-K/Akt
signalling pathway.
Description of regulatory roles for HMGA1 in the context of
apoptosis is not without precedent. HMGA1 has been found to
associate in vivo with p53 family members and inactivate their
functions. As such, overexpression of HMGA1 may lead to
suppression of p53-induced apoptosis and tumour-suppressing
activity (Frasca et al, 2006). In addition, antisense-mediated
suppression of HMGA1 expression in thyroid carcinoma and
pancreatic adenocarcinoma cell lines has been reported to induce
an apoptotic response (Scala et al, 2000; Trapasso et al, 2004). Our
findings that HMGA1 overexpression results in constitutive
activation of PI3-K/Akt pathway provide another mechanism
through which HMGA1 mediates its antiapoptotic functions.
HMGA1-dependent activation of Akt signalling is likely to protect
cancer cells from broad array of proapoptotic stimuli, not just
those related to anchorage deprivation. Indeed, we have recently
reported that HMGA1 protects pancreatic adenocarcinoma cells
from gemcitibine-induced apoptosis and in this context is a
potential molecular determinant of chemoresistance in pancreatic
cancer (Liau et al, 2006).
Our findings, taken together with those previously reported,
provide a mechanistic basis for conceptualising the known
correlations between HMGA1 expression and poor prognosis in
cancer patients (Chiappetta et al, 2004). These findings also have
obvious therapeutic implications. Future studies will need to
address whether targeted therapies directed against HMGA1 will
inhibit metastasis in pancreatic cancer.
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Figure 5 (A and B) Cellular proliferation was quantified by MTS assay
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